# Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B

> **NCT01843309** · PHASE4 · TERMINATED · sponsor: **Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran** · enrollment: 36 (actual)

## Conditions studied

- Patients With Fungic Infections

## Interventions

- **DRUG:** Spironolactone 100mg
- **DRUG:** Spironolactone 200mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01843309
- **Lead sponsor:** Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** Not possible to complete the sample within the estimated time by the use of new antifungals
- **Last updated:** 2015-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843309, "Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01843309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*